BioDelivery Sciences International Inc (BDSI)

3.76 -0.08  -2.08% NASDAQ Sep 25, 16:59 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
11/12/2020 16:30 EST Misc BioDelivery Sciences International Inc Third Quarter Earnings Conference Call for 2020
11/12/2020 Earnings BioDelivery Sciences International Inc Third Quarter Earnings for 2020 Release
08/05/2020 08:30 EDT Misc BioDelivery Sciences International Inc Second Quarter Earnings Conference Call for 2020
08/05/2020 Earnings BioDelivery Sciences International Inc Second Quarter Earnings Result for 2020
07/23/2020 Misc BioDelivery Sciences International Inc Annual General Meeting for 2019
05/07/2020 16:30 EDT Misc BioDelivery Sciences International Inc First Quarter Earnings Conference Call for 2020
05/07/2020 Earnings BioDelivery Sciences International Inc First Quarter Earnings Result for 2020
03/12/2020 16:30 EDT Misc BioDelivery Sciences International Inc Fourth Quarter Earnings Conference Call for 2019
03/12/2020 Earnings BioDelivery Sciences International Inc Fourth Quarter Earnings in 2019 Release
03/12/2020 Misc BioDelivery Sciences International Inc Annual Report for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.bdsi.com
  • Investor Relations URL: http://bdsi.investorroom.com/
  • HQ State/Province: North Carolina
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Nov. 12, 2020
  • Last Earnings Release: Aug. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence.

Top Fund Holders

Symbol Name Weighting
NEC213 Next Edge Bio-Tech Plus A 2.05%
FPBTRX FT Carolinas Leaders 2 RE 1.72%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.